Olmesartan Medoxomil + Hydrochlorothiazide

Generic Name

Olmesartan-medoxomil-hydrochlorothiazide

Other Names

• Olmesartan medoxomil and hydrochlorothiazide combination

Drug Class

• Angiotensin II receptor antagonist and thiazide diuretic

Chemical Formula

C14H12N2O8S.C24H32N6O4S

Molecular Weight

770.9 g/mol

Mechanism of Action

• Olmesartan medoxomil blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts.

Indications

• Hypertension in patients not adequately controlled with monotherapy and for whom combination therapy is appropriate

Common Dosage Forms

• Tablet

Typical Dosage

• 20 mg - 40 mg olmesartan/12.5 mg - 25 mg hydrochlorothiazide once daily

Pediatric Dosage

• Not established

Geriatric Dosage

• Dose adjustment may be needed based on renal function

Side Effects

• Dizziness
• Fatigue
• Orthostatic hypotension
• Hyperkalemia
• Renal impairment

Contraindications

• Anuria
• Hypersensitivity to sulfonamides or any component of the product

Pregnancy Category

• D

Lactation Safety

• L3 - Moderately Safe

Drug Interactions

• Lithium
• NSAIDs
• Potassium-sparing diuretics

Overdose Symptoms

• Hypotension
• Bradycardia
• Electrolyte depletion

Antidote for Overdose

• Supportive care and monitoring of electrolyte levels

Storage Conditions

• Store at room temperature away from moisture and heat

Pharmacokinetics

• Absorption: Olmesartan: Approximately 26% | Hydrochlorothiazide: Well absorbed
• Distribution: Olmesartan: Extensively distributed | Hydrochlorothiazide: Crosses the placenta
• Metabolism: Olmesartan: Minimal hepatic metabolism | Hydrochlorothiazide: Not extensively metabolized
• Excretion: Olmesartan: Feces (up to 55%) and urine (approximately 42%) | Hydrochlorothiazide: Urine (unchanged)

Precautions

• Renal impairment
• Hepatic impairment
• Electrolyte imbalances

Warnings

• Fetal toxicity
• Renal impairment
• Hypotension